MARKET

SRPT

SRPT

Sarepta Therapeutics Inc
NASDAQ
17.79
+0.39
+2.24%
After Hours: 17.85 +0.06 +0.34% 19:49 02/13 EST
OPEN
17.56
PREV CLOSE
17.40
HIGH
18.19
LOW
17.50
VOLUME
1.55M
TURNOVER
--
52 WEEK HIGH
114.41
52 WEEK LOW
10.42
MARKET CAP
1.86B
P/E (TTM)
-5.5810
1D
5D
1M
3M
1Y
5Y
1D
Sarepta’s First siRNA Move in Huntington’s Disease Could Be A Game Changer For Sarepta Therapeutics (SRPT)
Simply Wall St · 17h ago
Weekly Report: what happened at SRPT last week (0209-0213)?
Weekly Report · 21h ago
A Look At Sarepta Therapeutics (SRPT) Valuation After New Zealand Clears Huntington’s Disease Trial
Simply Wall St · 1d ago
Sarepta’s SRP-1005 Trial Approval Opens New Huntington’s Disease Opportunity
Simply Wall St · 3d ago
Has Sarepta Therapeutics (SRPT) Fallen Too Far After Its Sharp Multi‑Year Share Price Slide?
Simply Wall St · 5d ago
Press Release: Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2025 Financial Results
Dow Jones · 5d ago
SAREPTA THERAPEUTICS TO ANNOUNCE FOURTH QUARTER AND FULL-YEAR 2025 FINANCIAL RESULTS
Reuters · 5d ago
Analysts Offer Insights on Healthcare Companies: Vir Biotechnology (VIR), M3 (OtherMTHRF) and Sarepta Therapeutics (SRPT)
TipRanks · 02/09 11:40
More
About SRPT
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on helping patients through the discovery and development of ribonucleic acid (RNA)-targeted therapeutics, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. It has developed multiple approved products for the treatment of Duchenne muscular dystrophy (Duchenne) and is developing potential therapeutic candidates for a range of diseases and disorders, including Duchenne, Limb-girdle muscular dystrophies (LGMDs) and other neuromuscular and central nervous system (CNS) related disorders. The Company has developed and commercialized four approved products for the treatment of Duchenne: EXONDYS 51 (eteplirsen), Injection (EXONDYS 51), VYONDYS 53 (golodirsen) Injection (VYONDYS 53), AMONDYS 45 (casimersen) Injection (AMONDYS 45), and ELEVIDYS. Its pipeline includes over 40 programs at various stages of discovery, pre-clinical and clinical development.

Webull offers Sarepta Therapeutics Inc stock information, including NASDAQ: SRPT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SRPT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SRPT stock methods without spending real money on the virtual paper trading platform.